CA125 and HE4 distinguished endometrial cancer cases from healthy and symptomatic controls, with HE4 demonstrating potential utility as a biomarker in pre-menopausal women, in whom diagnosis is more challenging. This evidence concerns the gene MUC16 and endometrial cancer.